AXNX:NSD-Axonics, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 56.31

Change

-1.56 (-2.70)%

Market Cap

USD 2.42B

Volume

0.38M

Average Target Price

USD 62.83 (+11.58%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

-12.90 (-2.22%)

USD46.07B 101.02 85.49
PODD Insulet Corporation

-7.51 (-2.76%)

USD18.01B 2,719.60 170.35
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed, Inc

-4.21 (-1.38%)

USD13.81B 61.74 60.65
BRKR Bruker Corporation

+0.47 (+0.69%)

USD10.39B 67.20 32.95
IART Integra LifeSciences Holdings ..

-0.30 (-0.41%)

USD6.25B 37.10 22.89
TNDM Tandem Diabetes Care, Inc

-2.50 (-2.74%)

USD5.70B N/A N/A
SWAV ShockWave Medical, Inc

-1.82 (-1.21%)

USD5.49B N/A N/A
SDC SmileDirectClub, Inc

-0.24 (-2.79%)

USD4.12B N/A N/A
LIVN LivaNova PLC

-0.26 (-0.31%)

USD4.08B 77.40 N/A

ETFs Containing AXNX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.80% 49% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.80% 49% F 60% D-
Trailing 12 Months  
Capital Gain 60.84% 52% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.84% 52% F 55% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.66% 73% C 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.66% 73% C 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 46.81% 65% D 37% F
Risk Adjusted Return 82.59% 96% A 88% B+
Market Capitalization 2.42B 86% B 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.11 40% F 19% F
Price / Cash Flow Ratio -28.96 71% C- 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -23.35% 63% D 34% F
Return on Invested Capital -21.01% 61% D- 28% F
Return on Assets -11.96% 59% F 27% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.81 16% F 9% F
Short Percent 12.66% 18% F 16% F
Beta 0.05 90% A- 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.